Log in to save to my catalogue

Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patient...

Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patient...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11630754

Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma

About this item

Full title

Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma

Publisher

England: Oxford University Press

Journal title

The oncologist (Dayton, Ohio), 2024-12, Vol.29 (12), p.1003-1013

Language

English

Formats

Publication information

Publisher

England: Oxford University Press

More information

Scope and Contents

Contents

Platinum-based chemotherapy has been the standard first-line (1L) treatment for advanced urothelial carcinoma (UC) for decades, based on the proven efficacy and established safety profiles of cisplatin- and carboplatin-based regimens. With the emergence of novel regimens, it is important to reevaluate and contextualize the role of 1L platinum-based...

Alternative Titles

Full title

Reevaluating the role of platinum-based chemotherapy in the evolving treatment landscape for patients with advanced urothelial carcinoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11630754

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11630754

Other Identifiers

ISSN

1083-7159,1549-490X

E-ISSN

1549-490X

DOI

10.1093/oncolo/oyae215

How to access this item